AbbVie Inc. Other Comprehensive Income (Loss), Net of Tax
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Net of Tax of -$5.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-03
- AbbVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$5.00M, a 102.45% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$9.00M, a 104.92% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $430.00M, a 5.13% increase year-over-year.
- AbbVie Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$36.00M, a 120.11% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $781.00M, a 105.53% increase from fiscal 2024.
- AbbVie Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $380.00M.
- AbbVie Inc. other comprehensive income (loss), net of tax for fiscal 2023 was -$106.00M, a 115.14% decline from fiscal 2022.
- AbbVie Inc. other comprehensive income (loss), net of tax for fiscal 2022 was $700.00M, a 221.10% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.00M 10-Q · filed 2026-08-03 | -$14.00M 10-Q · filed 2026-08-03 | $416.00M derived: sum of 3 quarters · filed 2026-08-03 | $380.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$9.00M 10-Q · filed 2026-05-08 | $421.00M derived: sum of 2 quarters · filed 2026-05-08 | $385.00M derived: sum of 3 quarters · filed 2026-05-08 | $589.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $430.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $394.00M derived: sum of 2 quarters · filed 2026-02-20 | $598.00M derived: sum of 3 quarters · filed 2026-08-03 | $781.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$36.00M 10-Q · filed 2025-11-04 | $168.00M derived: sum of 2 quarters · filed 2026-08-03 | $351.00M 10-Q · filed 2025-11-04 | $760.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $204.00M 10-Q · filed 2026-08-03 | $387.00M 10-Q · filed 2026-08-03 | $796.00M derived: sum of 3 quarters · filed 2026-08-03 | $975.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $183.00M 10-Q · filed 2026-05-08 | $592.00M derived: sum of 2 quarters · filed 2026-05-08 | $771.00M derived: sum of 3 quarters · filed 2026-05-08 | $712.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $409.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $588.00M derived: sum of 2 quarters · filed 2026-02-20 | $529.00M derived: sum of 3 quarters · filed 2026-02-20 | $380.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $179.00M 10-Q · filed 2025-11-04 | $120.00M derived: sum of 2 quarters · filed 2025-11-04 | -$29.00M 10-Q · filed 2025-11-04 | $19.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$59.00M 10-Q · filed 2025-08-04 | -$208.00M 10-Q · filed 2025-08-04 | -$160.00M derived: sum of 3 quarters · filed 2026-02-20 | -$261.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$149.00M 10-Q · filed 2025-05-09 | -$101.00M derived: sum of 2 quarters · filed 2026-02-20 | -$202.00M derived: sum of 3 quarters · filed 2026-02-20 | -$222.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$53.00M derived: sum of 2 quarters · filed 2026-02-20 | -$73.00M derived: sum of 3 quarters · filed 2026-02-20 | -$106.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$101.00M 10-Q · filed 2024-11-04 | -$121.00M derived: sum of 2 quarters · filed 2024-11-04 | -$154.00M 10-Q · filed 2024-11-04 | $1.09B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$20.00M 10-Q · filed 2024-08-07 | -$53.00M 10-Q · filed 2024-08-07 | $1.19B derived: sum of 3 quarters · filed 2025-02-14 | $944.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | -$33.00M 10-Q · filed 2024-05-03 | $1.21B derived: sum of 2 quarters · filed 2025-02-14 | $964.00M derived: sum of 3 quarters · filed 2025-02-14 | $752.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $1.24B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $997.00M derived: sum of 2 quarters · filed 2025-02-14 | $785.00M derived: sum of 3 quarters · filed 2025-02-14 | $700.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | -$247.00M 10-Q · filed 2023-11-06 | -$459.00M derived: sum of 2 quarters · filed 2023-11-06 | -$544.00M 10-Q · filed 2023-11-06 | -$287.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$212.00M 10-Q · filed 2023-08-07 | -$297.00M 10-Q · filed 2023-08-07 | -$40.00M derived: sum of 3 quarters · filed 2024-02-20 | -$93.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$85.00M 10-Q · filed 2023-05-05 | $172.00M derived: sum of 2 quarters · filed 2024-02-20 | $119.00M derived: sum of 3 quarters · filed 2024-02-20 | $311.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $257.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $204.00M derived: sum of 2 quarters · filed 2024-02-20 | $396.00M derived: sum of 3 quarters · filed 2024-02-20 | $218.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$53.00M 10-Q · filed 2022-11-04 | $139.00M derived: sum of 2 quarters · filed 2022-11-04 | -$39.00M 10-Q · filed 2022-11-04 | $103.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $192.00M 10-Q · filed 2022-08-04 | $14.00M 10-Q · filed 2022-08-04 | $156.00M derived: sum of 3 quarters · filed 2023-02-17 | $332.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$178.00M 10-Q · filed 2022-05-06 | -$36.00M derived: sum of 2 quarters · filed 2023-02-17 | $140.00M derived: sum of 3 quarters · filed 2023-02-17 | $402.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $142.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $318.00M derived: sum of 2 quarters · filed 2023-02-17 | $580.00M derived: sum of 3 quarters · filed 2023-02-17 | $479.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $176.00M 10-Q · filed 2021-11-02 | $438.00M derived: sum of 2 quarters · filed 2021-11-02 | $337.00M 10-Q · filed 2021-11-02 | -$731.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $262.00M 10-Q · filed 2021-08-02 | $161.00M 10-Q · filed 2021-08-02 | -$907.00M derived: sum of 3 quarters · filed 2022-02-18 | -$944.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | -$101.00M 10-Q · filed 2021-05-07 | -$1.17B derived: sum of 2 quarters · filed 2022-02-18 | -$1.21B derived: sum of 3 quarters · filed 2022-02-18 | -$1.18B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | -$1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$1.10B derived: sum of 2 quarters · filed 2022-02-18 | -$1.08B derived: sum of 3 quarters · filed 2022-02-18 | -$1.12B 10-K · filed 2022-02-18 |
| 2019-09-30 | -$37.00M 10-Q · filed 2020-11-04 | -$12.00M derived: sum of 2 quarters · filed 2020-11-04 | -$48.00M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $25.00M 10-Q · filed 2020-08-04 | -$11.00M 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | $247.00M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |